Impact of test and treat with nirmatrelvir/ritonavir to mitigate the epidemic rebound when Zero-COVID ends in Wallis and Futuna
Résumé
Ending Zero-COVID is challenging, particularly when vaccine coverage is low. Considering Wallis and Futuna, a French Zero-COVID territory affected by reluctance to vaccination, low immunity and high levels of comorbidities, we investigate how targeted use of nirmatrelvir/ritonavir (brand name Paxlovid) can complement vaccination and non-pharmaceutical interventions (NPIs) and mitigate the epidemic rebound expected when Zero-COVID ends.
Fichier principal
manuscriptWF_hal_V2.pdf (1.83 Mo)
Télécharger le fichier
supplementaryMaterial_V1.pdf (609.5 Ko)
Télécharger le fichier
Origine | Fichiers produits par l'(les) auteur(s) |
---|
Origine | Fichiers produits par l'(les) auteur(s) |
---|